Louis J. DeGennaro
Directeur/Membre du Conseil chez BioTheryX, Inc.
Profil
Louis J.
DeGennaro is currently a Director at BioTheryX, Inc. He was previously the President & Chief Executive Officer at The Leukemia & Lymphoma Society, Inc. from 2014 to 2023.
Postes actifs de Louis J. DeGennaro
Sociétés | Poste | Début |
---|---|---|
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | Directeur/Membre du Conseil | - |
Anciens postes connus de Louis J. DeGennaro
Sociétés | Poste | Fin |
---|---|---|
The Leukemia & Lymphoma Society, Inc.
The Leukemia & Lymphoma Society, Inc. Miscellaneous Commercial ServicesCommercial Services The Leukemia & Lymphoma Society, Inc. operates as the world's largest voluntary health organization dedicated to funding blood cancer research, education and patient services. The firm provides treatment for , lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. It identifies and funds the most promising blood cancer research projects and forges partnerships with academic institutions, biotechnology and pharmaceutical companies to accelerate the development of new therapies. The company is headquartered in Rye Brook, NY. | Directeur Général | 01/05/2023 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
The Leukemia & Lymphoma Society, Inc.
The Leukemia & Lymphoma Society, Inc. Miscellaneous Commercial ServicesCommercial Services The Leukemia & Lymphoma Society, Inc. operates as the world's largest voluntary health organization dedicated to funding blood cancer research, education and patient services. The firm provides treatment for , lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. It identifies and funds the most promising blood cancer research projects and forges partnerships with academic institutions, biotechnology and pharmaceutical companies to accelerate the development of new therapies. The company is headquartered in Rye Brook, NY. | Commercial Services |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | Health Technology |